Mineralys Therapeutics MLYS
NASDAQ MLYS
$21.10 -0.48 (-2.22%)
At close: Oct 21, 2026 · 4:00 PM EDT

Mineralys Therapeutics (MLYS) Debt Ratio (2026)

Updated

Mineralys Therapeutics' Debt Ratio came in at 0.15 for Q2 2026.

Analysis

Mineralys Therapeutics (MLYS) Debt Ratio (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 0.39
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 0.24
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 0.52
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 0.42
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 0.08
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 0.28
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 0.60
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 0.53
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 0.31
10 Mineralys Therapeutics 1.79 Bn -765.35 Mn - 0.15
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.15
API Access

Mineralys Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=MLYS&period=max&api_key=YOUR_API_KEY